885 1030
[13]
Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retro- pubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 2009;27:607–12.
[14]
Bacon C, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001;166:1804–10.
[15]
Borchers H, Kirschner-Hermanns R, Brehmer B, et al. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results. BJU Int 2004;94:805–11.[16]
Evans JR, Zhao S, Daignault S, et al. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol 2015;116: 179–84.
[17]
Jeldres C, Cullen J, Hurwitz LM, et al. Prospective quality-of-life outcomes for low-risk prostate cancer: active surveillance versus radical prostatectomy. Cancer 2015;121:2465–73.[18]
Kobuke M, Saika T, Nakanishi Y, et al. Prospective longitudinal comparative study of health-related quality of life in patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer. Acta Med Okayama 2009;63:129–35.
[19]
Malcolm JB, Fabrizio MD, Barone BB, et al. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for local- ized prostate cancer. J Urol 2010;183:1822–8.
[20]
Namiki S, Satoh T, Baba S, et al. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. Urology 2006;68:1230–6.[21]
Pardo Y, Guedea F, Aguilo F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hor- monal treatment. J Clin Oncol 2010;28:4687–96.[22]
Pinkawa M, Asadpour B, Piroth MD, et al. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer—a matched-pair compari- son. Radiother Oncol 2009;91:225–31.[23]
Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358–67.[24]
Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92: 1582–92.[25]
Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long- term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol 2015;68:600–8.[26]
Resnick MJ, Koyama T, Fan KH, et al. Long-term functional out- comes after treatment for localized prostate cancer. N Engl J Med 2013;368:436–45.[27]
Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.[28]
Schapira MM, Lawrence WF, Katz DA, McAuliffe TL, Nattinger AB. Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care 2001;39:243–53.[29]
Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM. Measuring patients’ expectations regarding health-related quality- of-life outcomes associated with prostate cancer surgery or radio- therapy. Urology 2006;68:1224–9.
[30]
Barocas DA, Alvarez J, Resnick MJ, et al. Association between radia- tion therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA 2017;317: 1126–40.[31] MacLennan S, Williamson PR, Bekema H, et al. A core outcome set
for localised prostate cancer effectiveness trials. BJU Int. In press.
http://dx.doi.org/10.1111/bju.13854 .[32]
Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367: 203–13.[33]
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899–905.
[34]
Bellardita L, Valdagni R, van den Bergh R, et al. How does active surveillance for prostate cancer affect quality of life? a systematic review. Eur Urol 2015;67:637–45.[35]
Popiolek M, Rider JR, Andren O, et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 2013;63:428–35.[36]
Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011;12:891–9.[37]
Taylor KL, Luta G, Miller AB, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer con- trols in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. J Clin Oncol 2012;30:2768–75.[38]
Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the functional assessment of cancer therapy—prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 2009;12:124–9.
[39]
Skolarus TA, Dunn RL, Sanda MG, et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology 2015;85:101–5.[40]
Whiting PF, Moore TH, Jameson CM, et al. Symptomatic and quality of life outcomes following treatment for clinically localized pros- tate cancer: a systematic review. BJU Int 2016;118:193–204.[41]
Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treat- ments for clinically localized prostate cancer. Ann Intern Med 2008;148:435–48.[42]
Chen RC, Chang P, Vetter RJ, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst 2014;106:1–7.
[43]
Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762–71.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 6 9 – 8 8 5
885